Fosun closes HK IPO, but bankers can’t muster a cheery response

Fosun Pharmaceutical this week closed Hong Kong’s largest IPO in more than three months, selling a HK$3.97bn ($512m) deal. But the offering was not without its hiccups and took some restructuring to get across the finish line, quelling any urges among ECM bankers to celebrate its completion, writes Louisa Burwood-Taylor.